Remove Resources Analytical-technologies-services
article thumbnail

Reaction Biology to acquire Vyant Bio subsidiary’s operations in US

Pharmaceutical Technology

Reaction will also obtain lab facilities, equipment, staff, cell lines and expertise in toxicology, pharmacology, pathology and bio analytics from vivoPharm. This will further extend Reaction's industry-leading drug discovery service suite for customers in the biopharmaceutical sector.

In-Vivo 130
article thumbnail

Companion Diagnostics Services: Future of Outsourcing

Roots Analysis

In the recent years, service industry has become a fast-growing segment in the overall healthcare domain – thanks to the steady increase in demand for contract research organizations (CROs) and contract manufacturing organizations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time.

article thumbnail

SLAS2024: Day One Highlights

Drug Discovery World

Software-as-a-service company Xavo is promoting its new AI-driven scheduling solution Copilot, created to optimise resource allocation and increase lab throughput. The collaboration is part of the Danaher Beacons program and aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients.

article thumbnail

CMO checklist: Selecting a partner that’s right for you?

Pharmaceutical Technology

Companies may look at one service today, but will likely expand their scope in the future, so it’s important that the provider can evolve with a given project.??. While a potential service provider’s capabilities and track record should be well understood, companies shouldn’t choose a CMO based just on cost. Process Flow diagram?

article thumbnail

Is your digital communication strategy up to par?

pharmaphorum

He is enthusiastic about what he refers to as the “complete revolution” being experienced by healthcare, which will usher in new treatments, new technologies and new mindsets and values. Amy Hutnik is general manager, agency, advisory and evidence services at EVERSANA. Mark Mulder is vice president, commercial, Europe, at EVERSANA.

article thumbnail

Improving trial predictability: leveraging AI-powered analytics to guide trial design, strategy, and operations

pharmaphorum

Using data-informed insights derived by effectively implemented datasets, artificial intelligence/machine learning capabilities, and technology sponsors can realise increased predictability in their study planning from protocol design through enrolment strategy. Critical analysis in protocol design. per protocol, respectively.

Trials 98